A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) (NCT06343805)
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
🩺 Plain-English Summary (8th-Grade Level)
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Institute — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Stanford Cancer Institute — Palo Alto, California
- Moffitt Cancer Cancer Center — Tampa, Florida
- University of Kansas Medical Center — Kansas City, Kansas
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Washington University School of Medicine — St Louis, Missouri
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- MD Anderson Cancer Center — Houston, Texas
- AP-HP Hopital Saint-Louis — Paris,
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola — Bologna, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy
- Hospital General Universitario Gregorio Maranon — Madrid, Spain
- Hospital Clinic Barcelona — Barcelona,
- Hospital Universitario Ramon y Cajal — Madrid,
- Guy's Hospital — London, UK
- Genesis Cancer Care UK Limited - Oxford — Oxford, UK
📞 Contact the Study Coordinator
Phone: (917) 410-7250
Email: david@ajaxtherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- Decitabine in Treating Patients With Myelofibrosis — Chicago, Illinois
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.